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enables a high degree of accuracy in dose delivery. Nevertheless, 
the identification of a dominant intraprostatic lesion (DIL) on 
TRUS is challenging. With the advent of multiparametric 
magnetic resonance imaging (mpMRI), it is possible to identify a 
location of excess of tumour cells location that are especially 
aggressive. Unfortunately the geometry of the prostate on TRUS 
and on mpMRI may be different, requiring a deformable fusion to 
map a DIL identified on mpMRI. This study evaluates a novel 
automated deformable registration algorithm developed in-
house for mpMRI-to-TRUS DIL fusion. 
Methods and Materials: Five patients with low- and 
intermediate-risk prostate cancer treated as part of a Phase II 
clinical trial approved by our institutional research ethic board 
were included in this study. All patients had a predominant 
PIRADS 4-5 intraprostatic nodule identified on mpMRI. An 
automated deformable registration was then accomplished as a 
three-part process: 1) convert each of the two datasets into 
distance maps; 2) register the MRI distance map to the TRUS 
distance map using a rigid affine transformation; and 3) perform 
a basis-spline (B-spline) deformable registration between the 
two datasets. An MRI assisted TRUS based real-time prostate 
HDR-BT was delivered afterward. A single fraction of 19 Gy 
prescribed as a minimal dose to the prostate was delivered with 
the DIL to receive a D90 ≥ 23 Gy up to 28 Gy (tertiary objective). 
To evaluate the accuracy of the automatic deformable 
registration algorithm, a radiation oncologist was asked to 
cognitively register the lesion on mpMRI on the intraoperative 
TRUS dataset. Correlation between the observer’s contours and 
the automated contours were compared using the Dice similarity 
coefficient. The average distance from the edges of the observer 
and automated contours were reported in each of the cardinal 
directions.  
Results: The mean Dice coefficient for the prostate volumes was 
0.88 ± 0.01. The mean Dice coefficient for the DIL was 0.76 ± 
0.04. The mean difference in the anterior and posterior edge of 
the automated versus human contours was 0.93 ± 0.89 mm and 
0.26 ± 0.26 mm respectively. The mean difference in the superior 
and inferior edge of the automated versus human contours was 
2.19 ± 1.72 mm and 1.55 ± 1.44 mm respectively. The mean 
difference in the lateral edge of the automated versus human 
was 1.13 ± 0.38 mm as opposed 2.58 ± 1.8 mm in the medial 
edge. 
Conclusions: The automated deformable registration algorithm 
objectively and reliably transposes the DIL identified on mpMRI 
imaging into the TRUS based prostate HDR-BT workflow. Caution 
should be exercised when using automated contour based 
algorithms, with careful QA of the resultant co-registration. 
Particular scrutiny should be directed at the sup-inf and med-lat 
extents of the DIL resulting from the fusion. 
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Background:  Radiotherapy is an effective and comparably low-
cost cancer treatment. It has been estimated that 50% of cancer 
patients require radiation treatment. Lung cancer is the most 
commonly diagnosed cancer globally, and 77% of patients 
diagnosed with lung cancer will need radiotherapy. Despite this, 
evidence from around the world suggests that radiotherapy for 
lung cancer and other cancers continues to be under-utilized for 
reasons unrelated to patient need. Traditionally in radiation 
oncology, the majority of research has been focused on 
improving scientific knowledge and technical aspects of therapy. 
However, achieving the outcomes that these innovations allow is 
often hampered by system factors such as the complexities of 
matching demand for radiotherapy with supply of radiotherapy 
services. Consequently, there is a great need to measure actual 
and optimal use of radiotherapy and to identify and research 
modifiable factors that contribute to sub-optimal utilization of 
multimillion-dollar high-precision radiation treatment centres. 
The lack of availability of comprehensive information on 
characteristics that influence the performance of radiotherapy 
programs has limited the design and management of their 
services. As a result, planning has often been directed by expert 
opinion rather than objective evidence. The consequences of 
such an approach can be unpredictable, which in turn can lead 
to inefficient and inadequate care. In an era of high-precision 
radiotherapy, the greatest imprecision is still failing to deliver 
radiotherapy when it is indicated. In order to improve the 
delivery of precision radiotherapy services, a better 
understanding of factors affecting the demand for radiotherapy 
is needed.  
We propose a study to begin to address this, focusing on lung 
cancer as an example. 
Recently, Cambridge University has developed The MALTHUS 
Project: An application of mathematical models of radiotherapy 
demand for local and national capacity planning using Monte-
Carlo simulation techniques. The MALTHUS model is a form of 
Evidence-Based Requirements Analysis (EBRA). EBRA identifies 
indications for radiation therapy for a specific population based 
on systematic literature reviews. It then used an epidemiologic 
approach to calculate how frequently these indications for 
radiotherapy occurred in the population. This information is 
synthesized in order to estimate an appropriate rate of 
radiotherapy utilization. Delaney, Barton et al. expanded its use 
to all cancer sites and EBRA-type models are now broadly used 
for resource planning. Compared to some historical EBRA models, 
the MALTHUS model has the advantage of taking into 
consideration treatment complexities and dose fractionation of 
radiotherapy, which results in a more accurate demand 
quantification.  
A second method of demand estimation, “Benchmarking,” draws 
from the business world practice of comparing outcomes against 
the toughest competitor. In a radiotherapy context, 
benchmarking utilizes regions with cancer centres without major 
access barriers as the standard. This method assumes that 
experts are making “perfect” decisions about radiotherapy 
indications and that patients have unrestricted access to 
services. Criticism of the benchmarking method to assess health 
outcomes lies in its assumption of optimal structures, processes 
and practices, all of which have not been proven. 
The overall population’s need for radiotherapy will change 
according to the different proportions of cancers and stages of 
cancer found in different populations, geography, as well as 
patient factors such as functional status, age, and comorbidity. 
To tailor the model to a specific country or health setting 
requires data on the distribution of tumour types and stages as 
well as geographical and demographic factors. The MALHTUS 
model can be used to examine factors associated with regional 
variation in current demand and can also be used to predict 
future demand. 
Proposed Study:  We propose a comparative analysis between 
Ontario and England of the estimated need for external beam 
radiotherapy for lung cancer based on the MALTHUS model. The 
analysis will provide insights characterizing the extent to which 
patient-related and disease-related factors that drive the need 
for radiotherapy resources.  
This study will build on previous models of radiotherapy 
utilization and will be a collaborative approach with multiple 
international stakeholders.  The results of this study will aim to 
optimize utilization of high-precision radiotherapy in quantifying 
the impact of patient factors, disease factors, and treatment 
factors on estimating demand of radiotherapy.   
Hypotheses:  
1) That evidence-based estimates of need for radiotherapy for 
lung cancer will vary widely between health delivery units 
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and between countries.  
2) This variation will relate to patient factors, disease-related 
factors, and treatment factors. 
3)  That regional variation in need for radiotherapy for lung 
cancer predicted by the MALTHUS model will be greater than 
that seen with a benchmark approach to optimal utilization.  
Methods:  The MALTHUS model for radiotherapy demand will be 
utilized in order to investigate factors associated with regional 
variation in need for radiotherapy for lung cancer patients. 
MALTHUS decision trees for 23 disease sites have been 
established. The proximal branches of the tree encodes for 
cancer site, stage distribution, and treatment modality 
indication. Distal branches contain detailed information about 
how radiation is delivered, such as fractionation. MALTHUS takes 
into account local variation in cancer incidence, disease stage, 
performance status, and co-morbidity. It draws on high-quality 
cancer incidence data collected from national Cancer Registries 
and the National Cancer Intelligence Network (NCIN). It 
simulates demand at local, regional and national levels, and 
draws comparisons with actual radiotherapy activity from the 
British National Health Service’s (NHS) Radiotherapy Dataset 
(RTDS). The resulting data can be used to study the effects of 
differences in clinical opinion over best practice, and can assist 
local oncologists and service managers in developing and 
assessing business plans.  
We will update the British data with direct access to the National 
Cancer Intelligence Database that, from previous work, has been 
properly curated for the use of this model. Data will be stratified 
for age, tumor characteristics, stage distribution, and region 
subdivided at the county level. The model will then be adapted 
to the appropriate treatment indications and dose fractionations 
using national evidence based best practice guidelines. 
We will quantify the influence of patient-related factors (age, 
sex, comorbidity, functional status), disease-related factors 
(cancer incidence, cancer stage), and treatment factors 
(hypofractionation including usage of SBRT) on regional (NHS 
Primary Care Trust level) demand for radiotherapy for lung 
cancer. In univariate analysis, factors will be defined 
categorically and demand for radiotherapy by variable category 
will be described. The influence of these factors will be further 
investigated in univariate sensitivity analysis. The consequences 
of applying regional extremes in each variable’s distribution on 
national radiotherapy demand will be considered. For 
multivariate sensitivity analysis, a Monte Carlo (MC) simulation 
method will be utilized.  Confidence intervals from MC simulation 
will be compared against ranges of proposed evidence-based 
benchmarks to compare model performance and precision. 
Potential differences in the influence of key factors influencing 
demand may exist between countries. As a second phase, we 
anticipate to adapt the model to the population of lung cancer 
patients in Ontario for comparison of outcomes. Population-
based data from the Ontario Cancer Registry (OCR) will be 
utilized. This will include data on cancer incidence, and 
collaborative stage information. Data on age distribution by 
county from OCR will be used to estimate regional differences in 
performance status and comorbidity. 
Significance: A primary benefit of this model is its potential to 
elucidate what influences demand for radiotherapy patients. 
Demand, and by the same token, wait lists, are affected by an 
increase in the incidence of cancer, by the increase in the 
referral of patients for radiotherapy, and by an increase in dose 
fractionation per course of radiotherapy. All of these factors are 
reflected in the MALTHUS. As the public system has a fixed global 
budget and lacks the reserve needed to expand capacity quickly 
in radiotherapy, an accurate prediction of future demand is vital 
in our situation. Comparing Canadian and British data utilizing 
MALTHUS should increase generalizability in its projections and 
may identify national differences in the impact of key factors 
driving demand. Reliable, well-characterized models are 
needed, as it can take years in working closely with policy makers 
in order to influence officials to provide adequate capacity for 
high-precision radiotherapy.  
Radiation therapy has major oncological benefits, and small 
incremental gain in health system performance can translate into 
large societal benefits. Health Services Research in its nascent 
stages in the field of Radiation Therapy, therefore there is a 
significant amount of knowledge and skills that can be gained by 
young investigators. Results of this research program will have a 
direct link to many global institutions. ESTRO and QUARTS are 
currently exploring optimal infrastructure for radiation therapy 
around Europe, a project funded by the European Commission. 
Moreover, this comparative analysis will supplement data 
utilized for Activity Based Costing and Cost Benefit research that 
ESMO is currently undertaking.  
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Purpose: Current lung parenchyma dose reduction strategies do 
not take into account the relative contribution of different lung 
regions. The addition of functional information at the time of 
treatment planning could preferentially save the most functional 
parts and reduce the risk of toxicity. The purpose of this study 
was to quantify lung function based on a DECT-derived iodine 
map in patients treated with radiotherapy for lung cancer, as 
well as to assess the dosimetric impact of its integration in 
radiotherapy planning.  
Methods and Materials: Patients treated with stereotactic 
ablative radiotherapy (SABR) for early stage or intensity-
modulated radiotherapy (IMRT) for locally advanced lung cancer 
were prospectively enrolled in this study. A DECT in treatment 
position was obtained at time of treatment planning. Single 
Photon Emission Computed Tomography / Computed 
Tomography (SPECT/CT) and pulmonary function tests were 
obtained for validation purposes. Relative contribution of each 
voxel to the total lung function was based on iodine 
concentration. Composition of each voxel was determined with 
a Matlab (MathWorks) script based on a three material 
decomposition. The functional map was integrated in treatment 
planning system using 6 sub-volumes of varying iode 
concentration levels. Percent lung volume receiving 5 Gy (V5), 
V20 and mean dose (MLD) to whole lungs (anatomical) versus 
functional lungs were compared using bilateral paired Student T 
tests.  
Results: Results from 20 consecutive patients, including 16 
patients treated with SABR and four patients with IMRT, are 
presented. Sixty percent had known chronic obstructive 
pulmonary disease. Median forced expiratory volume in one 
second was 62% of predicted (29-113%) and median diffusing 
capacity of the lung for carbon monoxide was 56% (39-91%). 
There was a strong correlation between DECT and SPECT/CT-
derived lung function (r = 0.8, p = 0.0001). Mean V5, V20 and 
MLD variation between functional (weighted dosimetry) and 
anatomical lung volumes was 16% (0-48%, p = 0.03), 5% (1-15%, p 
= 0.12) and 15% (1-43%, p = 0.047), respectively.  
Conclusions: DECT-derived iodine map correlates well with 
SPECT/CT and its integration in treatment planning is associated 
with significant differences in V5 and mean dose to functional 
lungs. Future work will focus on selection of patients most likely 
to benefit from function-sparing IMRT. 
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